

Remarks/Arguments


Applicants have amended the specification to provide the priority claim. Claims 14-17 have been amended. Claims 12-13 have been cancelled without prejudice for resubmission. Claims 1-11 and 14-23 are pending after entry of this amendment. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Attorney Docket No. 100885-1P US.

Respectfully submitted,



Name: Jianzhong Shen
Dated: May 4, 2005
Reg. No. 48,076
Phone No. 302-886-8854

Global Intellectual Property, Patents,
AstraZeneca,
1800 Concord Pike,
Wilmington,
DE-19850-5437